{"name":"Oragenics","slug":"oragenics","ticker":"OGEN","exchange":"NYSE American","domain":"oragenics.com","description":"Oragenics is a biopharmaceutical company focused on developing novel anti-infective and oral health products. The company's lead product, NTCD-M3, is a novel antimicrobial peptide for the treatment of respiratory tract infections. Oragenics has a strong pipeline of products in various stages of development, including a Phase 2 clinical trial for NTCD-M3. The company is well-positioned to capitalize on the growing demand for novel anti-infective treatments.","hq":"Tampa, FL","founded":2003,"employees":"~10","ceo":"Michael Sullivan","sector":"Anti-Infectives / Oral Health","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$100M","metrics":{"revenue":37653,"revenueGrowth":0,"grossMargin":0,"rdSpend":2392658,"netIncome":-9842487,"cash":4399726,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"NTCD-M3 patent cliff ($0.0B at risk)","drug":"NTCD-M3","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Oragenics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Oragenics reported its financial results for the fourth quarter and full year 2023, with a net loss of $4.4 million and $17.6 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Oragenics Announces Collaboration with University of Florida to Develop Novel Antimicrobial Peptides","summary":"Oragenics entered into a collaboration with the University of Florida to develop novel antimicrobial peptides for the treatment of respiratory tract infections.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFA1Z0JUQkIwSTQ2dlc4YU5ELTE4dll5SkZjVnQ1NEk1SE1NcTBFUEFUUmdHTUNnTnpuYVdPYnU5OXhkdEZZSkhmNjBFWGs0NXY3RkZyaHZYeFFyeUh4OTRv?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"OGEN Stock Price, Quote & Chart | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill","headline":"OGEN Stock Price, Quote & Chart | ORAGENICS INC (NYSEARCA:OGEN)","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1LM0V3cVJqYUVtYkg4MS10M1JHcktobFVFWnFoallfZ1lMN1RURkMtajVKYWZvLUhDUjd2aWVpeVVXb3Nra011LXhCTS1ya3ZJc0RNdXg4dXgxMW95YjRXUmpJMGxrZDhtNE1zWk1R?oc=5","date":"2026-03-23","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Oragenics (OGEN) - Stock Titan","headline":"If You Invested $1,000 in Oragenics (OGEN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOWkFJTXdRWVJDNzhybzVrd180dTJxc1dYYXYzSXIzYXhuci1TalZ3a0daQ01zZHFxOWo3b1R0MHBKLW9UeTBSWmlSQnRwa1Q0NEdXVGVTTExQcVRJVkNubE5sWVBsOXExak0yN0VsVng3SXVSU1dDMUxJNVlYVF9mV1FueEF6bHBlaTlQNUdqMDZPdEE4NURnUFFmVlh1ZXJKSmlkUXB0eTAxajdMLW5FRXlXOC0weHFRdXF0Q1lYR05NREZK?oc=5","date":"2026-03-17","type":"pipeline","source":"The Globe and Mail","summary":"ORAGENICS FILES ANNUAL REPORT ON FORM 10-K - The Globe and Mail","headline":"ORAGENICS FILES ANNUAL REPORT ON FORM 10-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQcGpycnNOOUE3cVpteXBtS0R3Rm92cjZnUGJUR0ZiMUV4M2FPaWtWWVpDeC0tX3RGRF9aM2NOWHpCc2I4c0xBd3NSOFM2YWJYN2M5c3VjNkRqYTJEc0k5eldCTlFpSjhqRHItcjF6d2Z4c3otTE5RMi02cE9LTnY3MmlzLWRyZ3N3dFE5OVpDQXdsT3ozXy1Fbzl6OA?oc=5","date":"2026-03-17","type":"trial","source":"Stock Titan","summary":"Biotech Oragenics raises $16.5M, clears debt to fund concussion drug trial - Stock Titan","headline":"Biotech Oragenics raises $16.5M, clears debt to fund concussion drug trial","sentiment":"neutral"},{"date":"2026-03-16","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNam5EWG9HTklLSjFrOHdjSU85MndXSUtkV3d4WUROdXltaG5JVTM1OFNOWnIyNS1janlhU3hvM2htYUlqeUFNaVp2TUVTYU9vOFJWUk1vc0Y5MGM1R0RHckZWMFUwNzg5NjNKWVpmdmZNekJnV2NwWWJqbmhyRVQxb0J0My0yWU1fX0E?oc=5","date":"2026-02-04","type":"regulatory","source":"Yahoo Finance","summary":"Oragenics partners with Duck Flats Pharma to support FDA IND trial design - Yahoo Finance","headline":"Oragenics partners with Duck Flats Pharma to support FDA IND trial design","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOX2VTZEZnbUo4bFJYNUJfQXNXUGw4SklaVE42ZWh0R1FiVFc0cXJIVFVsOGhmRXJPRXowdk16bVNQd3NZQnBDVW1JTEpfS29OQ2ZxWmVuLUlJeTJlT1RuX0ZSbXRUZUtXeWNtaVNra1BDLTJ2RG1kdzhDM292ZGtyckJoQXU4ZzltVUE?oc=5","date":"2026-02-03","type":"regulatory","source":"Yahoo Finance","summary":"Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program - Yahoo Finance","headline":"Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program","sentiment":"neutral"},{"date":"2026-01-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTFBxZndiUXo3Q0E1QlNFYk12ZFVGWmFWM2EtaDhDUDBGYkZiZkdnUmpxeDIwellnR3RmcW5tMjdQdUpBZmNsakVVS0h6R3pwZldkRm15MkU3elNhd3JMbE5YaHZGUTFFNXpicVQtaVpwMmk?oc=5","date":"2025-07-31","type":"regulatory","source":"MarketBeat","summary":"Oragenics (OGEN) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"Oragenics (OGEN) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFA3VEF4cExfS0hXRW5BVHdCdm8ySk94c0dwN1JTM1RqN1JNUmpXRXBka1V0WFFGMnRld3VDLU9oazdLTzBxRzd6TlFrOHJJYzdK?oc=5","date":"2024-02-08","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"NTCD-M3","drugSlug":"ntcd-m3","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Pfizer","Merck & Co.","Johnson & Johnson"],"therapeuticFocus":["Anti-Infectives","Oral Health"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":0,"period":"2018-12-31"},{"value":0,"period":"2018-09-30"},{"value":0,"period":"2018-06-30"},{"value":0,"period":"2018-03-31"},{"value":0,"period":"2017-12-31"},{"value":0,"period":"2017-09-30"}],"grossProfit":0,"grossProfitHistory":[],"rdSpend":2392658,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-9842487,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":4399726,"cashHistory":[],"totalAssets":10067764,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}